TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, p... by Quoix, Elisabeth, Prof, Lena, Hervé, MD, Losonczy, Gyorgy, Prof, Forget, Frédéric, Prof, Chouaid, Christos, Prof, Papai, Zsolt, Prof, Gervais, Radj, MD, Ottensmeier, Christian, Prof, Szczesna, Aleksandra, Prof, Kazarnowicz, Andrzej, MD, Beck, Joseph T, MD, Westeel, Virginie, Prof, Felip, Enriqueta, Prof, Debieuvre, Didier, MD, Madroszyk, Anne, MD, Adam, Julien, MD, Lacoste, Gisèle, MD, Tavernaro, Annette, MSc, Bastien, Bérangère, MSc, Halluard, Céline, MSc, Palanché, Tania, PhD, Limacher, Jean-Marc, MD

Get full text

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an o... by Thatcher, Nick, Prof, Hirsch, Fred R, Prof, Luft, Alexander V, MD, Szczesna, Aleksandra, MD, Ciuleanu, Tudor E, Prof, Dediu, Mircea, MD, Ramlau, Rodryg, Prof, Galiulin, Rinat K, MD, Bálint, Beatrix, MD, Losonczy, György, Prof, Kazarnowicz, Andrzej, MD, Park, Keunchil, MD, Schumann, Christian, Prof, Reck, Martin, MD, Depenbrock, Henrik, MD, Nanda, Shivani, MS, Kruljac-Letunic, Anamarija, PhD, Kurek, Raffael, MD, Paz-Ares, Luis, MD, Socinski, Mark A, Prof

Get full text

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled p... by Paz-Ares, Luis, Dr, Mezger, Jörg, Prof, Ciuleanu, Tudor E, Prof, Fischer, Jürgen R, MD, von Pawel, Joachim, MD, Provencio, Mariano, Prof, Kazarnowicz, Andrzej, MD, Losonczy, György, Prof, de Castro, Gilberto, MD, Szczesna, Aleksandra, MD, Crino, Lucio, MD, Reck, Martin, MD, Ramlau, Rodryg, Prof, Ulsperger, Ernst, MD, Schumann, Christian, MD, Miziara, Jose Elias A, MD, Lessa, Álvaro E, MD, Dediu, Mircea, MD, Bálint, Beatrix, PhD, Depenbrock, Henrik, MD, Soldatenkova, Victoria, MSc, Kurek, Raffael, MD, Hirsch, Fred R, Prof, Thatcher, Nick, FRCP, Socinski, Mark A, Prof

Get full text

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial by Fehrenbacher, Louis, Dr, Spira, Alexander, MD, Ballinger, Marcus, PhD, Kowanetz, Marcin, PhD, Vansteenkiste, Johan, Prof, Mazieres, Julien, Prof, Park, Keunchil, Prof, Smith, David, MD, Artal-Cortes, Angel, MD, Lewanski, Conrad, MD, Braiteh, Fadi, MD, Waterkamp, Daniel, MD, He, Pei, PhD, Zou, Wei, PhD, Chen, Daniel S, MD, Yi, Jing, PhD, Sandler, Alan, MD, Rittmeyer, Achim, MD

Get full text

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study by Cappuzzo, Federico, Dr, Ciuleanu, Tudor, MD, Stelmakh, Lilia, MD, Cicenas, Saulius, Prof, Szczésna, Aleksandra, MD, Juhász, Erzsébet, MD, Esteban, Emilio, MD, Molinier, Olivier, MD, Brugger, Wolfram, MD, Melezínek, Ivan, MUDr CSc, Klingelschmitt, Gaëlle, MSc, Klughammer, Barbara, PhD, Giaccone, Giuseppe, Prof

Get full text

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial by Pirker, Robert, Prof, Pereira, Jose R, MD, Szczesna, Aleksandra, MD, von Pawel, Joachim, MD, Krzakowski, Maciej, Prof, Ramlau, Rodryg, MD, Vynnychenko, Ihor, MD, Park, Keunchil, Prof, Yu, Chih-Teng, MD, Ganul, Valentyn, Prof, Roh, Jae-Kyung, Prof, Bajetta, Emilio, Prof, O'Byrne, Kenneth, Prof, de Marinis, Filippo, MD, Eberhardt, Wilfried, MD, Goddemeier, Thomas, Dipl Stat, Emig, Michael, MD, Gatzemeier, Ulrich, MD

Get full text